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Abstract
Irvalec is a marine-derived antitumor agent currently undergoing phase II clinical trials. In vitro, Irvalec induces a rapid loss
of membrane integrity in tumor cells, accompanied of a significant Ca2+ influx, perturbations of membrane conductivity,
severe swelling and the formation of giant membranous vesicles. All these effects are not observed in Irvalec-resistant cells,
or are significantly delayed by pretreating the cells with Zn2+. Using fluorescent derivatives of Irvalec it was demonstrated
that the compound rapidly interacts with the plasma membrane of tumor cells promoting lipid bilayer restructuration. Also,
FRET experiments demonstrated that Irvalec molecules localize in the cell membrane close enough to each other as to
suggest that the compound could self-organize, forming supramolecular structures that likely trigger cell death by necrosis
through the disruption of membrane integrity.
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Introduction
Irvalec (Elisidepsin, PM02734) is a synthetic cyclodepsipeptide
closely related to Kahalalide F, a natural antitumor compound
isolated from the Hawaiian marine mollusc Elysia rufescens [1].
Preliminary in vitro and in vivo studies identified Irvalec as a new
antiproliferative drug with activity against a broad spectrum of
tumor types [Molina-Guijarro JM et al.; AACR Annual Meeting
2009; abstr 888]. In patients, the compound is well tolerated and
does not show the signs of toxicity commonly observed with
standard anticancer treatments [2]. Irvalec is currently in phase II
clinical studies for squamous non-small cell lung cancer (NSCLC),
gastric and esophageal cancer.
It was previously reported that Kahalalide F induces a rapid
membrane permeabilization, with loss of mitochondrial mem-
brane potential and of lysosomal integrity, and profound general
alterations in the cells, including severe cytoplasmic swelling and
vacuolization, dilatation and vesiculation of the endoplasmic
reticulum, mitochondrial damage and plasma membrane rupture
[3–5]. Other groups have reported that Kahalalide F interferes
with different signaling pathways such as EGFR, HER2/neu,
ErbB3, TGF-a or PI3K/AKT. Kahalalide F mediates a necrotic
cell death type rather than apoptosis that is not associated with
DNA degradation or cell cycle blockade [6].
Concerning Irvalec, a functional screening assay performed on
a collection of 4,848 viable Saccharomyces cerevisiae haploid deletion
mutants [7] showed that proteins involved in vesicle trafficking
appear to be important for the activity of Irvalec. Thus, yeast cells
defective in these pathways were more sensitive to the drug than
their wild-type counterparts whereas a mutant strain lacking the
sphingolipid fatty acyl 2-hydroxylase Scs7 (orthologue to human
FA2H) was found to be the most resistant strain. In fact,
overexpression of Scs7/FA2H in yeast or mammalian cells
rendered them more sensitive to the drug. Although not yet fully
understood, it seems that fatty acid 2-hydroxylation is important
for the maintenance of membrane conformation and integrity in
some tissues.
Here we show that the potent cytotoxic activity of Irvalec is
exerted very rapidly through insertion of the drug molecule into
the plasma membrane and induction of drastic loss of membrane
integrity. As a result, severe cell swelling, formation of giant
vesicles (GVs), a significant Ca2+ influx and alterations in cell
membrane conductivity are detected. These membrane changes
were not observed in tumor cells with acquired resistance to the
compound. Moreover, these cytotoxic effects could be delayed by
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pretreating the cells with Zn2+, which has been described as a
membrane protector [8]. These results indicate that Irvalec
interacts directly with the cell membrane and induces a rapid
and severe disorganization of the lipidic bilayer of tumor cells that
disturbs the water-electrolyte balance causing necrosis.
Materials and Methods
Reagents
Irvalec (C77H125F3N14O18, MW:1591.89) (Figure S1) and its
fluorescent derivatives were manufactured at PharmaMar, SA.
Stock solutions (10 mM in DMSO) were prepared and stored at
220uC. Sulforhodamine B (SRB), 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), TrizmaH base, Hoechst-
33342, propidium iodide (PI), Dulbecco’s modified Eagle’s
medium (DMEM), penicillin, streptomycin and fetal calf serum
(FCS) were purchased from Sigma (St. Louis, MO, USA). Calcein
acetoxymethylester (calcein-AM) was purchased from Calbiochem
(Cambridge, MA, USA). AlexaFluor-488 conjugated b-subunit
cholera toxin, and Fura2/AM were purchased from Invitrogen
(Carlsbad, CA, USA). The lipophilic fluorescent probe 2-
carboxyethyl-1,6-diphenyl-1,3,5-hexatriene (PA-DPH) was from
Molecular Probes (Eugene, USA).
Cell lines
A panel of cell lines was used representing the following cancerous
tissue types: cervix (HeLa), prostate (PC-3 and 22Rv1), pancreas
(PANC-1 and MiaPaca-2), ovary (IGROV-1, IGROV-1/ET and
A2780), lung (NCI-H460, NCI-H23 and A549), liver (SK-HEP-1
and HepG2), leukemia, (MOLT-4 and K-562), renal (RXF 393 and
Caki-1), gastric (HGC-27 and HS 746T), colon adenocarcinoma
(LoVo, LoVo/Dox, HT-29 and HCT-116), and breast (MDA-MB-
231, MCF-7 and BT-474). Human embryonic kidney cells (HEK-
293) were cultured in DMEM (Gibco, Invitrogen) supplemented
with 10% bovine fetal serum, penicillin-streptomycin (Sigma) and
non-essential amino acids 1% as previously described (Arias et al.,
2007). IGROV-1/ET and LoVo/Dox are cell lines that over-
express the P-glycoprotein. All these cell lines were purchased from
the American Type Culture Collection and grown with the
appropriate culture media supplemented with 10% FCS, 1%
penicillin and streptomycin and 2 mM L-glutamine.
The resistant variant A549-Irv was developed from the A549
lung cancer cells using stepwise increases of concentration of
Irvalec over an 18-month period. The maximum concentration
used during selection was 50 mM.
Cell viability assays
Cells were seeded in 96-well microtiter plates and allowed to
stand for 24 hours at 37uC and 5% CO2 in drug-free medium
before treatment with vehicle alone or Irvalec at the concentrations
and times indicated in the text. For cell survival quantification,
MTT was added to the cell cultures for 8 h. Then, the culture
medium was carefully removed and the colored formazan crystals
dissolved in DMSO. The absorbance of the samples was measured
at 540 nm using a microplate spectrophotometer. Results are
expressed as percentage of control cell survival and represent the
mean of at least three independent experiments. For short time
treatment assays (30 min), a colorimetric assay using SRB, as
previously described [9], was used.
Membrane permeabilization assays
For time-course experiments, cells were seeded at high density
in 96-well clear-bottom black plates and cultured as described
above. When confluence was reached, fresh culture medium
(supplemented with 25 mM HEPES pH 7.4 and 50 mg/mL PI)
containing or not different concentrations of Irvalec was added.
The uptake of PI was quantified by plate fluorimetry (531/
632 nm) at 37uC, up to 70 min (1 min intervals), using a Victor-3
Multilabel Counter (Perkin Elmer). Results were expressed as
relative fluorescent signals. In a different experimental setting, the
cells were loaded with 1 mM calcein-AM for 15 min, then washed
to remove excess calcein-AM and further cultured in medium
containing 25 mM HEPES (pH 7.4) with or without Irvalec at the
indicated concentrations. Calcein fluorescence decrease was
monitored by fluorescence microscopy. Finally, cells were cultured
in 60 mm Petri dishes and treated with vehicle alone or with the
appropriate concentration of Irvalec in a final volume of 4 mL.
For the quantification of the LDH (lactate dehydrogenase)
enzymatic activity, the commercially available LDH-Cytotoxcity
Assay Kit (BioVision) was used following the manufacturer’s
instructions.
Cytosolic Ca2+ imaging
The effects of Irvalec on Ca2+ concentration dynamics were
performed as previously described [10,11]. Briefly, A549 (56105)
cells were plated on 12 mm poly-L-Lysine-coated glass coverslips
and loaded with 4 mM fura2/AM for 60 min at room temperature
in 1 ml of standard medium containing 145 mM NaCl, 5 mM
KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM glucose and 10 mM
HEPES (pH: 7.42). Cells were then placed on the heated (37uC)
stage of an inverted microscope (Zeiss Axiovert S100 TV). Cells
were perfused continuously with 37uC pre-warmed standard
medium and epi-illuminated alternately at 340 and 380 nm. Light
emitted above 520 nm was recorded with an OrcaER digital
camera (Hamamatsu Photonics, Shizuoka, Japan). Pixel by pixel
ratios of consecutive frames were captured every 5 s.
Electrophysiological recordings
The effects of Irvalec on membrane conductance were analyzed
in A549, HCT-116, HEK-293 and HeLa cells as previously
described [12–16]. Experiments were performed in a small bath
mounted on the stage of an inverted microscope (Nikon model
TMS, Garden City, NY) continuously perfused with the
extracellular solution (Tyrode-glucose buffer). Ion currents were
recorded at room temperature (20–22uC) using the whole-cell
voltage-clamp configuration of the patch-clamp technique [17]
with an Axopatch 1C patch-clamp amplifier (Axon Instruments,
Foster City, CA). Currents were filtered at 2 kHz (four-pole Bessel
filter), sampled at 4 kHz. Data acquisition and command
potentials were controlled by the CLAMPEX program of
PCLAMP 6.0.1 software (Axon Instruments). Micropipettes were
pulled from borosilicate glass capillary tubes (Narishige, GD-1,
Tokyo, Japan) on a programmable horizontal puller (Sutter
Instrument Co., San Rafael, CA) and heat-polished with a
microforge (Narishige). Pipette tip resistance averaged between 1
and 3 MV. The intracellular pipette solution contained (in mM):
K-aspartate 80, KCl 50, phosphocreatine 3, KH2PO4 10, MgATP
3, HEPES-K 10, EGTA 5 and was adjusted to pH 7.25 with
KOH. The external solution contained (in mM): NaCl 130, KCl
4, CaCl2 1.8, MgCl2 1, HEPES-Na 10, and glucose 10, and was
adjusted to pH 7.40 with NaOH. Measurements were performed
using the CLAMPFIT program of PCLAMP 9.2.
Two-photon fluorescence lifetime imaging
Two-photon fluorescence-lifetime imaging (2P-FLIM) of live cells
was carried out on a MicroTime200 system (PicoQuant, Germany)
coupled with an Olympus IX71 inverted microscope mounted with
a 606water-immersion objective NA1.2. Each pixel is represented
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by the intensity-weighted average fluorescence lifetime of the pixel
total fluorescence intensity. Horizontal polarized excitation (Y
direction in the X-Y microscope plane) was performed by a mode-
locked, femtosecond-pulsed Ti:Sapphire laser (Mai-Tai, Spectra
Physics,CA) operating at a repetition rate of 80 MHz and tuned to
755 nm. For vertical polarization imaging the excitation polariza-
tion was interchanged from horizontal to vertically using a half-
wave plate. Two-color (Oregon Green 488 and AlexaFluor 555)
fluorescence images were acquired simultaneously with two single-
photon avalanche diodes (SPAD, SPCM-AQR-14, Perkin Elmer,
USA), through a dichroic beam splitter FF560-Di01 and bandpass
filters FF01-520/35, FF01-607/36 or 685/40 (Semrock, Germany).
Horizontal and vertically polarized fluorescence images were
acquired simultaneously using a polarization beamsplitter cube.
The excitation power (0.8–8 mW before the objective) was adjusted
using a variable optical attenuator LS-107AT (Lasing, S.A. Spain)
to achieve rates of counting lower than 106 photons/s. FLIM
X-Y scans were recorded at different Z values with a piezo
XY-scanning table and PiFoc Z-piezo (E-710 Digital PZT con-
troller, PI, Germany), with the time-correlated single-photon
counting (TCSPC) technique, by using a TimeHarp 300 PC-board
(PicoQuant, Germany), synchronized with the laser pulses.
Acquisition time per pixel accounted for 0.6 ms–1.2 ms, resulting
in image overall acquisition time of 60 s–180 s, depending on the
image resolution and the intensity of the fluorescence signal.
A549 cells grown on LabTek chambered coverglass slides
(Thermo Scientific-Nunc) were washed and incubated with
Tyrode-glucose buffer containing PA-DPH (0.5 mM) at 22uC for
10 min in the dark. In the assays performed with Irvalec-Oregon
Green 488 (Irv-OG488) and Irvalec-AlexaFluor 555 (Irv-A555)
stock solutions were 0.5 mM (in 100% DMSO) and were added to
the Tyrode-glucose buffer to the appropriate final concentration,
keeping DMSO at 0.4% v/v.
Statistical methods
Results are expressed as mean 6 SEM. Direct comparisons
between mean values in control conditions and in the presence of
drug for a single variable were performed by paired Student’s t-
test. Student’s t-test was also used to compare two regression lines.
Differences were considered significant if P,0.05.
Results
Cytotoxicity of Irvalec against human tumor cells
The cytotoxicity of Irvalec was studied in vitro in a panel of 23
human tumor cell lines, derived from 11 different tissues. Dose-
response curves were performed at 72 h and cell survival quantified
using the MTT method. Irvalec displayed cytotoxic activity with a
mean IC50 value of 2.3 mM. Table 1 shows the relative IC50 values
obtained for each cell line. Prostate (PC3 and 22RV1) and pancreas
(PANC-1 and MIA-PaCa) cell lines tended to be the most and least
sensitive, respectively. Cell lines over-expressing the P-glycoprotein
(IGROV-1/ET and LoVo/Dox) presented similar IC50 values than
their parental counterparts (IGROV-1 and LoVo) indicating that
the compound is not a substrate of this efflux pump.
Irvalec induces a necrotic cell death by affecting the cell
membrane
A549 (lung) and HeLa (cervix) cells were treated with Irvalec
(1 and 10 mM) and examined by phase contrast microscopy. While
at 1 mM there was any visible effect, at 10 mM both cell lines
showed similar rapid morphological changes. Within a few
minutes, treated cells showed evident membrane destabilization
as revealed by the appearance of cell swelling and abundant
membrane blebs and GVs (Figure 1A and Video S1). These
morphological changes were associated with necrotic cell death.
We then confirmed microscopically the effect of Irvalec on the
cell membrane by pre-treating A549 cells with fluorescent b-
subunit of the cholera toxin to label the plasma membrane, and
then treating them with 10 mM Irvalec. As shown in Figure 1B and
Video S2, cell GVs were clearly surrounded by fluorescently-
labelled plasma membrane. These effects were plasma membrane-
specific, since other cellular structures, such as lysosomes, were not
affected by the compound at short treatment times (Figure S2). We
finally performed parallel concentration-response cytotoxicity
curves at two different drug exposure times, 30 minutes and
72 hours, and observed a perfect overlaping of the curves (IC50
values of 3.5 mM and 1.8 mM, respectively) (Figure 1C), indicating
that the cytotoxic activity of Irvalec was directly associated with its
early ‘‘all’’ or ‘‘non’’ effects on the cell membrane.
Irvalec induces rapid membrane permeabilization in
tumor cells
We then evaluated whether exposure to Irvalec was associated
with a rapid loss of cell membrane integrity. A549 cells were
cultured in the presence of PI and exposed to the drug for different
time intervals. As shown in Figure 2A and Video S3, a rapid PI
Table 1. Cytotoxicity of Irvalec in a panel of 25 human cancer
cell lines.
Cell line* IC50 (mM)
Prostate PC3 0.660.3
22RV1 0.360.2
Pancreas PANC-1 .6.360
MiaPaCa-2 .6.360
Ovary IGROV-1 1.160.4
IGROV-1/ET* 0.960.1
A2780 1.360.2
Lung NCI-H460 5.560.3
NCI-H23 1.561.4
A549 1.860.5
Liver SK-HEP-1 1.560.7
HEPG2 0.360.1
Leukemia MOLT4 5.660.4
K562 2.960.1
Kidney RXF393 2.061.5
CAKI-1 2.460.8
Stomach HS746T 1.560.1
HGC-27 1.360.6
Colon LoVo 0.360.1
LoVo/Dox* 0.560.1
HT29 0.460.1
HCT-116 3.661.8
Breast MDA-MB-231 4.361.1
MCF-7 0.960.2
BT-474 0.360.1
*All cell lines were treated with increasing concentrations of Irvalec and cell
growth inhibitory concentration (IC50) was determined after 72 h by MTT
method. Values represent mean 6 SD of three different experiments.
**Cell lines over-expressing the P-glycoprotein.
doi:10.1371/journal.pone.0019042.t001
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uptake occurred after 2 minutes treatment with 10 mM Irvalec. To
confirm these results, A549 cells were pre-loaded with calcein-AM,
a permeable derivative of fluorescein. While non-treated cells
remained fluorescent, Irvalec treatment induced a rapid loss
(2 min) of fluorescence (Figure 2A; Video S4). Again, cell
membrane permeabilization was not observed at low concentra-
tions even at long treatment periods (.24 h) (data not shown).
We also studied the kinetics of membrane permeabilization
mediated by Irvalec in time-course experiments. A549 cells were
cultured in the presence of PI and exposed or not to different
concentrations of Irvalec (from 1 to 6 mM). The nuclear PI
fluorescence was measured in real time (1 min intervals) by
fluorometry. As shown in Figure 2B, Irvalec affected the
permeability of tumor cells in a time- and concentration-
dependent manner. At concentrations of 2–3 mM, Irvalec had
low to moderate permeabilization effects that showed a linear
dependency with time. At higher concentrations, 4–6 mM, the
effect of the drug was more drastic insofar as a significant loss of
membrane permeability was observed within the first minutes after
treatment. We finally analyzed the release of intracellular LDH
into the extracellular culture media as a measure of cell membrane
permeabilization. Cells were treated with Irvalec (1–6 mM) and
aliquots of the supernatants were taken at different time intervals
to evaluate the levels of LDH. As shown in Figure 2C, Irvalec
induced the release of LDH in a time- and concentration-
dependent manner, with a slower kinetics than that observed for
PI. Altogether, these results demonstrated that Irvalec induces
rapid membrane damage that alters the selective permeability of
cells to molecules of very different sizes (PI, calcein or LDH).
Irvalec elicits free Ca2+ movements across the cell
membrane
Next, we investigated the effects of 0.5 and 1 mM Irvalec on
cytosolic Ca2+ concentrations ([Ca2+]cyt) in Fura2-loaded A549
cells. As shown in Figures 3A-I and 3A-II, Irvalec treatment
promoted a rapid and large, concentration-dependent rise in
Figure 1. Irvalec induces a necrotic cell death. (A) Representative images of A549 and HeLa cells treated with Irvalec (1 and 10 mM) and
examined by phase contrast video-microscopy; pictures were taken 1 and 5 min after treatment. (B) Effects of 10 mM Irvalec at the cell membrane
A549 cells pre-treated with AlexaFluor 488-conjugated b-subunit of the cholera toxin to fluorescently label the plasma membrane; white arrows
indicate the formation of giant vesicles (C) Dose-response cytotoxicity curves to analyze the activity of Irvalec after 30 min (&) and 72 h (%)
incubation times using the SRB method. Results represent the mean6SD of at least three different experiments.
doi:10.1371/journal.pone.0019042.g001
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([Ca2+]cyt) at both concentrations. This was evidenced as shown
by the increase in the Fura2 fluorescence emission when samples
were excited at 340 nm and the decrease in Fura2 fluorescence
emission when the sample was excited at 380 nm leading to a
large rise in the ratio of both fluorescences (F340/F380 ratio).
Noteworthy, after treatment of A549 cells with both Irvalec
concentrations, some cells presented a sudden decrease of the
F340/F380 ratio probably caused by the cell permeabilization
and loss of the dye. To further investigate the permeability to
Ca2+ in A549 cells we used Mn2+ as a surrogate for Ca2+. Its
permeability can be followed in fura2 loaded cells because Mn2+
quenches fura2 fluorescence emissions at all excitation wave-
lengths. Treatment with 0.5 mM Irvalec quickly promoted sudden
decreases in the F340/F380 ratio in the presence of Mn2+ in A549
cells (Figure S3).
We then investigated whether the rise in [Ca2+]cyt was due to
extracellular or intracellular sources. For this purpose, A549 cells
were treated with 0.5 mM Irvalec in the absence of extracellular
Ca2+. Figure 3A-III shows that, under these conditions, Irvalec
was able to elicit only a small and transient rise in [Ca2+]cyt. Re-
addition of extracellular Ca2+ resumed the larger, typical effect of
Irvalec, suggesting that the rise in [Ca2+]cyt was mainly due to
extracellular Ca2+. When depleting intracellular Ca2+ stores using
thapsigargin (1 mM for 10 min) in Ca2+-free medium, 0.5 mM
Irvalec induced almost no change in [Ca2+]cyt thus confirming
that the Ca2+ was mainly coming from extracellular sources
(Figure 3A-IV). Again, re-addition of extracellular Ca2+ promoted
a every large rise in cytosolic Ca2+.
Irvalec disturbs cell membrane conductivity
As membrane damaging agents act by disrupting the normal
functioning of cell membranes, we also analyzed the effect of the
non-cytotoxic concentration of 1 mM Irvalec on membrane
conductivity in A549 cells. Figure 3B shows the current-voltage
relationship (IV) of the endogenous outward K+ current of A549
cells recorded after applying depolarizing 250-ms pulses from a
holding potential of 280 mV. The magnitude of this current
exhibited a mean value of 10806355 pA (n = 8), when cells were
pulsed from a holding potential of 280 mV to +60 mV and
measured at the end of a 250-ms pulse. The same figure also shows
(right panel) the current elicited after applying a ramp protocol
from 2100 mV to +120 mV during 500 ms [18].
In order to analyze the effects of 1 mM Irvalec, a series of ramps
from 2100 mV to +120 mV during 500 ms were applied. As
shown in Figure 3C, Irvalec produced an increase of the membrane
conductance at all membrane potentials that led to the appearance
of an in- and an out-ward current at negative and positive
membrane potentials, respectively. During the appearance of
Irvalec effects, a downward effect of the current during the
application of the ramp protocol was also observed (white arrows).
This type of effect is also observed when Kv1.5 channels are co-
expressed with the Kvb1.3 subunit that induces a fast and
incomplete inactivation of the current [14,19–21]. Also as shown
in Figure 3C, the time effects of Irvalec appeared within two phases,
due to the observed downward effect. The time lag between the
application of Irvalec and the beginning of the effects was 440645 s
(n = 4). Similar effects were observed when exposing HEK-293,
HeLa and HCT-116 cells to 1 mM Irvalec (data not shown).
Figure 2. Irvalec induces a concentration-dependent rapid membrane permeabilization. (A) Representative images of A549 cells exposed
to Irvalec 10 mM for 2 min. In the presence of propidium iodide (PI), unpermeabilized cells show intact nuclei (I) while permeabilized cells show PI
stained nuclei (II); in pre-loaded with calcein AM cells, the intracellular fluorescence (III) rapidly vanished from permeabilized cells upon Irvalec
treatment (IV) (scale bar: 50 mm) (B) Time-course of Irvalec-dependent membrane permeabilization of A549 cells using different concentrations of the
drug (ranging from 1 to 6 mM) as assessed by plate fluorimetry using PI nuclear staining; (C) Time-course of Irvalec-dependent membrane
permeabilization of A549 cells using different concentrations of the drug (ranging from 1 to 6 mM) as assessed LDH release.
doi:10.1371/journal.pone.0019042.g002
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Figure 3. Effects of Irvalec on cytosolic Ca2+ concentrations and cell membrane conductivity in A549 cancer cells. (A) Representation
of cytosolic Ca2+ concentration imaging records (F340/F380 ratio) in A549 cells. (I) Alteration in cytosolic Ca2+ after treatment with Irvalec 1 mM
(n=12); the panel corresponds to the mean 6 SEM values of [Ca2+]cyt in all cells for each experiment each microscopic field (II) Representation of
cytoplasmic Ca2+ concentration records in A549 cells after treatment with Irvalec 0.5 mM (n= 29); the panel corresponds to the mean6 SEM values of
[Ca2+]cyt in all cells for each experiment (III) Effects of removal of extracellular Ca2+ on the rise in cytosolic Ca2+ induced by 0.5 mM Irvalec; the graph
corresponds to the mean 6 SEM values of [Ca2+]cyt in all cells (n = 31) for two different experiments (IV) Effects of depletion of intracellular Ca2+
stores with 1 mM thapsigargin during 10 min on the rise in cytosolic Ca2+ induced by 500 nM Irvalec in Ca2+-free medium and after re-addition of
extracellular calcium; the panel corresponds to the mean 6 SEM values of [Ca2+]cyt in all treated cells (n = 29). (B) Electrophysiological characteristics
of A549 cells; left panel shows the current-voltage relationship obtained after applying the pulse protocol described in Experimental Procedures.
Amplitude of the potassium currents were measured at the end of 250 ms depolarizing pulses and were represented versus membrane potential.
Right panel shows the ion current elicited after applying a ramp pulse protocol from 2100 mV to +120 mV during 500 ms from a holding potential
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Zinc salts protect cells against the early cytotoxic effects
of Irvalec
Since Zn2+ has well established membrane-stabilizing proper-
ties, we investigated whether this cation could protect tumor cells
from Irvalec cytotoxicity. A549 cells were pre-treated or not with
10 mM ZnCl2 (a non-toxic concentration) and then treated with
5 mM Irvalec for 15 min in the presence of PI. As shown in
Figure 4A, treatment with Irvalec alone resulted in a rapid and
massive cell death. In contrast, cells pretreated with ZnCl2 were
significantly protected (Figure 4A and Video S5). In the absence of
ZnCl2, approximately 60% of the cells were permeabilized by
Irvalec while in its presence, less than 5% were affected. This
of280 mV (C) Electrophysiological effects of 1 mM Irvalec; left panels shows the amplitude of the maximum current at the end of the ramp. Note that
the downward of the current observed in the left panel is reflected in a plateau phase in the increase of the current; right panel shows original
records after applying a ramp pulse protocol from 2100 mV to +120 mV during 500 ms; white arrows shows a downward in the current.
doi:10.1371/journal.pone.0019042.g003
Figure 4. Zinc protects tumor cells against Irvalec cytotoxicity. (A) Representative images of A549 cells treated with 5 mM Irvalec alone or in
combination with 10 mM ZnCl2, in the presence of PI. Cell permeabilization was followed by fluorescence microscopy (red nuclear staining) (scale
bar: 50 mm) (B) Quantification of Irvalec induced cell permeabilization in real time, using plate fluorimetry. A549 cells were treated with 10 mM Irvalec
alone or in combination with different concentrations of ZnCl2 (ranging from 0.1 mM to 10 mM) in the presence of PI. Nuclear staining was measured
at intervals of 1 min and represented as relative signal from control fluorescence (C) Effect of ZnCl2 on the electrophysiological recording obtained in
A549 cells treated with Irvalec; cells were treated with the following solutions in a sequence, I: control conditions, II: ZnCl2 (10 mM), III: 1 mM Irvalec in
the presence of 10 mM ZnCl2 and IV: ZnCl2-free and Irvalec-free external solution.
doi:10.1371/journal.pone.0019042.g004
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represented a protection against Irvalec cytotoxicity in more than
90% of the cells that otherwise would be affected by the drug.
The ZnCl2 protective effect against Irvalec was also quantified
by means of PI fluorimetry experiments (Figure 4B). A549 cells
were treated with 10 mM Irvalec alone or in combination with
different concentrations of ZnCl2 for 70 minutes. PI staining was
analyzed by real-time plate fluorimetry (1 min intervals). ZnCl2
had a dose-dependent protective effect. At concentrations below
2.5 mM, ZnCl2 had a minor effect, exerting low or no protection
at all. At 5 mM, a partial protective effect was observed, while at
higher concentrations, 7.5 or 10 mM, the protection exerted by
ZnCl2 was nearly complete during the duration of the experiment.
Similar results were obtained when ZnSO4 was used in lieu of
ZnCl2 (data not shown).
We finally perfused A549 cells with several solutions and
measured the cell membrane conductivity in the following order:
control (Figure 4C-I), external solution containing 10 mM ZnCl2
(Figure 4C-II), external solution containing 10 mM ZnCl2 and
1 mM Irvalec (Figure 4C-III) and control external solution again
(Figure 4C-IV). Figure 4C shows the results of a typical membrane
conductivity experiment under these conditions (n = 3). Treatment
with 10 mM ZnCl2 produced changes both in the magnitude and
gating of the endogenous Kv1.5 channel expressed by these cells
(Figure 4C-II). As shown in this Figure, ZnCl2 increased the
magnitude of the current when measured at +120 mV (at the end
of the ramp) and shifted the threshold of the activation of the
current to more negative potentials (data not shown). After
washing the A549 cells with an external solution containing ZnCl2
and Irvalec (Figure 4C-III) a slight increase in the outward current
was observed without any increase in the inward conductance of
the current observed in the absence of ZnCl2 (Figure 3B). Only
during the wash-out with a ZnCl2- and Irvalec-free external
solution, the typical effects of Irvalec were observed (Figure 4C-
IV). Similar results were obtained in HCT-116 and HEK-293 cell
lines (data not shown). Altogether, these experiments clearly
indicated that strengthening the cell membrane architecture with
zinc salts diminished the drastic effects of Irvalec on the cell
membrane.
Characterisation of A549 cells resistant to Irvalec
A549-Irv cells were originated from A549 parental cells by a
classical stepwise selection procedure. As shown in Figure 5A, cells
were more than 30-fold more resistant to Irvalec than the parental
A549 cells. The IC50 values after 30 min or 72 h exposure were
5560.5 mM and 3460.5 mM, respectively (Figure 5A-I and
5A-II). This cell line did not express efflux pumps on the cell
membrane and did not show any cross resistance with other
common anticancer agents (Figure S4 and Table S1). Incubation
of A549-Irv with 10 mM Irvalec did not alter the cell membrane
integrity and did not induce necrotic cell death (Figure 5B) as
occurred in the parental A549 cells (Figures 1 and 2). Irvalec
treatment also failed to induce any rise in [Ca2+]cyt in the resistant
subline at concentrations of 0.5 mM or 1 mM (Figure 5C). Addition
of Mn2+ 1 mM did not induce any decreases in the F340/F380
ratio, as expected (Figure 5C). As shown in the current records,
A549-Irv cells were completely insensitive to 1 mM Irvalec effects,
as no changes in membrane conductance were observed
(Figure 5D). Altogether, these results indicated that in A549-Irv
cells Irvalec treatment was unable to induce any alteration in cell
membrane integrity.
Irvalec inserts into the plasma membrane
Since the effect of Irvalec was associated with rapid and dramatic
changes in the plasma membrane integrity, we used two-photon
time-resolved (TFTR) imaging to investigate whether the com-
pound directly integrated into the plasma membrane. First, we took
advantage of the characteristics of the lipophilic dye PA-DPH to
obtain information about the effect of Irvalec on the lipid
reorganization of the plasma membrane. PA-DPH localizes to the
plasma membrane, placed parallel to the lipid acyl chain axis, with
average fluorescence lifetimes of about 6.6 ns, and no partition
preference between the gel and fluid phase phospholipids is shown.
Interestingly, this cylindrical molecule has absorption and fluores-
cence emission dipoles aligned parallel to its long molecular axis that
allows measurements of lipid order when polarized light microscopy
is used.
Adherent cultures of A549 cells were grown on chambered
slides, washed and labeled with 1 mM PA-DPH, treated with 2 mM
Irvalec, and observed with TFTR fluorescence microscopy.
Figure 6A shows representative 2P-FLIM pictures of the
experiment. PA-DPH emission is distributed near homogeneously
all over the plasma membrane of A549 untreated cells with
intensity average fluorescence lifetimes of about 4.5 ns. The
acquired 2P-FLIM images, both in the horizontal (Figure 6A-I)
and vertical (Figure 6A-II) polarization excitation directions, show
details of the roughness of the plasma membrane of untreated cells
at sub-mm resolution. These polarization images also show that the
cell membranes kept a fluidic phase, in which the PA-DPH
molecules still have freedom of movement. Furthermore, PA-DPH
labels internal membranes/vesicles or cytoplasm components with
an average fluorescence lifetime of about 3 ns (green-yellow colors
in Figures 6A-I and -II). A549 cells treated with Irvalec showed
membrane restructuring, and displayed GVs in which the dye lost
freedom of movement and was efficiently excited only when the
light polarization was perpendicular to the bilayer plane
(Figures 6A-III and -IV). The GVs in Irvalec-treated cells were
clearly labeled by PA-DPH and showed the strongest fluorescence
in the direction parallel to the excitation polarization. Since this
effect is directly related with the organization of the phospholipids,
these results indicate that the lipids in the GVs are highly ordered.
In the fluid phase, the photoselection effect would decrease
because of the relatively low lipid order. Thus, Irvalec affected the
fluidity of the plasma membrane phospholipids, inducing the
formation of GVs in which the ordered phase predominates over
the fluid phase.
We then used a fluorescently labeled Irvalec analog (Irvalec-
Oregon Green 488; Irv-OG488) (Figure S5A) to further investigate
the membrane effects of the drug. Adherent cultures of A549 cells
were grown on chambered slides before being treated with Irvalec
(Figure 6B-I). Then, cells were washed and treated with Irv-OG488
in Tyrode-glucose buffer and analyzed by fluorescence microscopy
(Figure 6B-II to -VI). Surprisingly, when observed with TFTR
microscopy, most of the A549 cells treated with non-cytotoxic
concentrations of Irv-OG488 did not show any significant
fluorescence in the plasma membrane (Figure 6B-II). Only a
residual minor fluorescent labeling was observed in the extracellular
fluid. The lack of fluorescence in the plasma membranes could be
due to self-quenching of the dye when the Irv-OG488 molecules are
(somehow) packed. After addition of unlabeled Irvalec, at cytotoxic
concentrations, the fluorescence signal rapidly appeared in the
plasma membrane (Figure 6B-III), probably due to some kind of
organization of membrane-bound Irvalec molecules in the lipid
bilayer. Then, all of a sudden, GVs started to form and cells died in
a necrotic process (Figures 6B-IV and -V). The plasma membrane
of affected cells only appeared labeled when a mix of labeled and
unlabeled Irvalec was added. This was taken as an indication that
Irv-OG488 may be organized in multimeric complexes in the
affected plasma membrane. When cells were treated with a mix of
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Irv-OG488 and unlabeled Irvalec, the latter presumably intercalate
between the former, thus avoiding OG-488 self-quenching of Irv-
OG488 multimers. The same effect was observed when cells were
treated with the AlexaFluor 555 derivative of Irvalec, Irv-A555
(Figure 6B-VI). In contrast, A549-Irv cells treated with a mix of Irv-
OG488 and unlabeled Irvalec (final concentration: 4.6 mM) did not
show any significant fluorescence in the plasma membrane; all the
fluorescence came from the media and cells images appear as
negative images (Figure S6A). Moreover, treated A549-Irv cells did
not present any severe swelling or formation of giant membranous
vesicles. Of note, a careful screening of the whole preparation
allowed us to find a low percentage of cells (,5%) that showed Irv-
OG488 interacting with the plasma membrane (Figure S6B); this
specific cell population showed a much lower fluorescence signal of
Irv-OG488 compared with the A549 sensitive cells in the same
experimental conditions. Taken together, these results suggest that,
at non-cytotoxic concentrations, Irvalec is evenly distributed
throughout the cell membrane but forms some kind of assembly
after a critical concentration is reached in A549 sensitive but not in
the A549-Irv cells.
To further investigate whether Irvalec was evenly distributed
through the cell membrane or was forming patches within the
lipid bilayer at different drug concentrations, A549 adherent cells
were treated with 0.5 mM Irv-OG488 (energy donor), 1.8 mM
Irv-A555 (energy acceptor; Figure S5B) and 2.4 mM Irvalec. We
then performed time-resolved fluorescence resonance energy
transfer (FLIM-FRET) experiments. As shown in Figure 6C, both
fluorescent Irvalec derivatives localized mainly to the plasma
membrane, although some amount of intracellular fluorescence
was also observed. The intensity-average fluorescence lifetime of
Irv-OG488 bound to the plasma membrane shifts to the green
(donor channel, Figure 6C-I and -II) due to resonant energy
transfer to Irv-A555 molecules in the very near vicinity (distances
OG488-A555 lower than 50 A˚).
Importantly, both fluorescent compounds form patches in
the plasma membrane, and in some specific intracellular
locations, near the nucleus, where the chromophores were close
enough (around 50 A˚) to efficiently permit FRET. This effect
was not seen in the intracellular membranes stained with both
dyes, probably due to more unstructured insertions of the
Figure 5. Characterization of Irvalec-resistant A549-Irv cells. (A) Dose-response cytotoxicity curves to analyze the activity of Irvalec in A549-
Irv after exposure of 30 minutes (I) and 72 h (II); results represent the mean6SD of at least three different experiments (B) Effects of Irvalec treatment
in cell membrane permeabilization; representative images of A549-Irv cells exposed to vehicle or to 10 mM Irvalec for 10 min are shown. Resistant
cells kept cell morphology, did not show propidium iodide staining and retained preloaded calcein-AM in the cytoplasm (scale bar: 50 mm) (C) Effects
of Irvalec treatment on cytosolic Ca2+; the left panel shows the effects of 0.5 mM Irvalec on cytosolic Ca2+ concentration (n = 27); the right panel
represents the fura2 F340/F380 ratio in the presence of Mn2+ after treatment with 0.5 mM Irvalec (n = 16) (D) Effects of Irvalec treatment on cell
membrane conductivity; left panel shows original records after applying a ramp pulse protocol from 2100 mV to +120 mV during 500 ms. Right
panel shows the amplitude of the maximum current at the end of the ramp.
doi:10.1371/journal.pone.0019042.g005
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compounds that remained at longer distances. Also, we did
not observe FRET when cells were treated with a mix of Irv-
OG488 and Irv-A555 at non-cytotoxic Irvalec concentrations
(data not shown), which confirms that Irvalec molecules
were only grouped in the plasma membrane at cytotoxic
concentrations.
Figure 6. Interactions between Irvalec and the plasma cell membrane. For these experiments, A549 cells were grown on LabTek chambered
slides; 2P-FLIM images are representative of different experiments. (A) Visualization of changes in the plasma cell membrane organization in A549
cells without (I and II) or after treatment (III and IV) with 2 mM Irvalec. A549 cells were labelled with 1 mM PA-DPH and excited with polarized light
microscopy. The direction of the linear polarized excitation beam is shown in the figure with red arrows: Horizontal (I and III) and Vertical (II and IV);
Emission filter: 483/32; I–II: (XY section, Z = 0), III–IV (XY section, Z = 5 mm) (B) Localization of Irvalec in the cell membrane; A549 cells were treated with
Irv-OG488 or Irv-A555 and analyzed by two-photon time-resolved fluorescence microscopy; I: untreated cells (XY section, Z = 0); II: cells treated with
0.6 mM of Irv-OG488 (XY section, Z = 0); III: cells treated with 2.2 mM of a mix of Irv-OG488 and Irvalec (1:4.5) (XY image, Z = 0); IV and V: cells treated
with 0.4 mM of a mix of Irv-OG488 and Irvalec (1:3) (IV: XY image, Z = 5 mm; V: XZ section, Y position defined by white arrow in IV); VI: cells treated with
2 mM of a mix of Irv-A555 and Irvalec (1:4). (XY section, Z = 10 mm); emission bandpass filters; I–V: FF01-520/35; VI: FF01-607/36; Total intensity scale in
arbitrary units: 0–1(I, IV–VI); 0–2(II); 0–50 (III). (C) Representative example of time-resolved fluorescence resonance energy-transfer (FLIM-FRET)
experiments in A549 cell exposed to a mix of 0.6 mM Irv-OG488, 1.8 mM Irv-A555 and 2.4 mM Irvalec; I (XY section, Z = 0) and II (YZ section, X position
defined by white arrow in I): donor channel image (OG488); III (XY section, Z = 0) and IV (YZ section, X position defined by white arrow in III): acceptor
channel image (A555); donor filter: FF01 520/35; acceptor filter: FF01 685/40; dichroic beam splitter: FF560-Di01; total intensity scale in arbitrary units:
0–7 (I–II); 0–1 (III–IV). Scale bar: 10 mm.
doi:10.1371/journal.pone.0019042.g006
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Discussion
Here we have shown that low micromolar concentrations of
Irvalec induced a rapid cell death that occurs within minutes after
drug treatment and in a wide variety of cell types. The
characteristic ‘‘z’’ shape of the dose-response curves usually
obtained with Irvalec, suggested that the drug needs to achieve a
critical concentration in the cell to exert its cytotoxic action.
Through dose-response cytotoxicity curves, we demonstrated that
the short- (30 min) and long-term (72 h) effects of Irvalec on cell
viability were virtually the same. This observation can be taken as
an indication that the compound induced a drastic disruption of
cellular homeostasis within minutes after treatment. Moreover, the
fact that other organelles such as lysosomes were apparently not
affected at short time exposures, suggests that Irvalec is acting
primarily on the plasma membrane.
The rapid mode of cell killing after cell membrane damage is
normally associated with a necrotic cell death, which is
characterized by cellular swelling, plasma membrane rupture
and loss of intracellular contents. All of these morphological and
physiological events were confirmed in cells treated with Irvalec.
Shortly after treatment with effective concentrations of the drug, a
visible swelling process began, accompanied by massive blebbing
and complete loss of membrane integrity, as evidenced by the
permeabilization to PI. Loss of membrane integrity was further
evidenced by the detection of intracellular components, such as
LDH or pre-loaded calcein in the culture medium. The
electrophysiological changes observed after acute exposure of
different cell types to Irvalec suggest that the compound is able to
modify the plasma membrane in such a way that it becomes
permeable to ions (e.g Ca2+ and Mn2+) even when the cell is not
pulsed (since the holding current was changed from ,10 pA to
,10 nA).
These results are in agreement with previous data reported
by other authors for Irvalec and Kahalalide F in other cell systems
[3–5,7,22]. In yeast systems, Irvalec treatment was related to the
formation of plasma membrane invaginations and necrotic cell
death [7]. The activity of Kahalalide F against the protozoan
Leishmania spp was recently associated to the alteration of the
plasma membrane of the parasite [22]. In mammalian tumor cells,
Kahalalide F was reported to cause changes in the osmotic balance
of the cell that would finally induce cytoplasmic swelling and
oncotic cell death [3,4]. These authors postulated that the
mechanism of action of Kahalalide F was similar to that of other
cytotoxic peptides which induce cell death through the formation
of pores in the membrane and/or by changing the activity of
existing channels [5,23].
To further demonstrate the important role of membrane
disorganization in the cytotoxicity of Irvalec, we preincubated
the tumor cells with zinc salts, which have been demonstrated to
have membrane-stabilizing properties [24]. We show here that
Zn2+ exerted a significant protective effect against the cytotoxicity
of Irvalec as it prevented both the morphological changes
associated with the necrotic process and the rapid permeabiliza-
tion of the plasma membrane. Also, at the electrophysiological
level, Zn2+ attenuated the Irvalec-induced alterations. In fact, Zn2+
significantly increases membrane anisotropy, which is accompa-
nied by an increase in order parameter in membrane preparations.
Therefore, we can speculate that this effect of ZnCl2 on the fluidity
of the lipid bilayer avoids the effects of Irvalec.
The role of the cell membrane as the main target of Irvalec was
subsequently confirmed in A549-Irv cells, a cell line that shows
specific resistance to Irvalec. When treated with effective, necrotic
concentrations of Irvalec, the resistant cells were completely
insensitive. In fact, drug treatment did not induce any rise in
[Ca2+]cyt or any changes in membrane conductance or in
membrane permeability thus indicating that these cells might
have acquired specific alterations in their cell membrane that
rendered them resistant to drug treatment. In yeast models,
resistance to Irvalec was associated to the deficiency of the
sphingolipid fatty acyl 2-hydroxylase Scs7 (orthologue to human
FA2H) indicating that the presence of fatty acid 2-hydroxylation
should be important for the maintenance of a membrane
conformation required for drug activity [25,26]. However,
A549-Irv cells did not present any alteration in the expression of
FA2H (data not shown). Experiments are currently underway
aimed to identify the cell membrane alterations related to Irvalec
resistance.
Using fluorescent derivatives of Irvalec, along with the lipophilic
membrane biomarker PA-DPH and two-photon time-resolved
imaging, we have demonstrated that the compound rapidly
interacts with the plasma membrane of tumor cells, causing lipid
bilayer restructuration and somehow altering its fluidity and
normal physicochemical properties. Of interest, the interaction of
fluorescent derivatives of Irvalec was not observed in A549-irv
cells. Interestingly, it was also demonstrated, by using FRET, that
at cytotoxic concentrations Irvalec molecules are forming some
kind of assemblies all throughout the plasma membrane where the
individual molecules of the drug are close enough to each another
(less than 50 A˚) as to let us suggest that the compound self-
organizes in the plasma membrane, forming supramolecular
structures that could trigger the disruption of membrane integrity.
The idea of Irvalec forming a supramolecular organization in
the membrane to exert its cytotoxic action is in agreement with its
behaviour in the cytotoxicity experiments, where it would need
first to reach a critical local concentration to self-organize and
form the cytotoxic structures that finally produce the drastic lytic
effect. Other explanation for this particular behavior could be the
fact that eukaryotic cells have specific and efficient mechanisms to
overcome and repair sporadic membrane insults coming from
quite different sources. Tumor cells could be triggering these
repair mechanisms in the presence of low concentrations of
Irvalec, totally counteracting the cytotoxic action of the com-
pound, while at higher concentrations of the drug, the repair
mechanisms are overcome resulting in rapid cell death. Ca2+ plays
an important role in this repair mechanism, mediating exocytosis
of proximal lysosomal vesicles to clamp the membrane at the sites
of damage. This process is thought to be mediated by a rapid
increase of intracellular Ca2+, most likely due to activation of
extracellular Ca2+ uptake by specific mechanisms. Supporting this
idea, we found that Irvalec rapidly alters Ca2+ dynamics in treated
cells, promoting a rise in cytosolic Ca2+ concentrations. This
increase was mainly due to Ca2+ entry, indicating cell membrane
permeabilization after drug treatment. In some cells (those that
would finally die by necrosis) the Ca2+ increase was quickly
followed by cell permeabilization in all the cells. These dramatic
changes in Ca2+ permeability across the plasma membrane may
contribute to explain its dose-dependent toxicity.
Most conventional anticancer agents need to enter cancer cells in
order to exert their cytotoxic activity. On the other hand, cancer
cells frequently become resistant to these agents as a consequence of
increased expression of drug efflux pumps or drug-detoxifying
enzymes or the appearance of defects in the cellular apoptotic
machinery. Thus, the development of new classes of anticancer
drugs that act at the cell surface and that are unaffected by common
mechanisms of chemoresistance would be a major advance in
cancer treatment. One of the major caveats that should encounter
molecules acting at the cell membrane level is non-specificity
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towards tumor cells. In these sense, results from xenografted tumors
in animal models and phase I clinical data demonstrated that
Irvalec presents antitumor activity without inducing major adverse
effects [1,2]. Whether this is due to specific characteristics of the cell
membrane of tumor cells or to subtle effects at non-cytotoxic
concentrations that could drive to some more specific events in
tumor cells is not known and studies are currently conducted in our
laboratory to elucidate these matters.
In conclusion, our results strongly suggest that Irvalec rapidly
and irreversibly targets the plasma membrane of tumor cells,
altering its normal architecture and function. After reaching a
critical, effective concentration, the compound appears to self-
organize and give rise to highly cytotoxic molecular structures that
trigger the lytic process characteristic of necrotic cell death.
Supporting Information
Figure S1 Chemical structure of Irvalec.
(TIF)
Figure S2 Effects of Irvalec on lysosomes. A549 cells were
pre-treated with both lysotracker, to label the lysosomes, and
AlexaFluor 488-conjugated beta subunit of cholera toxin, to label
the plasma membrane, and then treated with Irvalec (10 mM).
Representative images are shown.
(TIF)
Figure S3 Representation of Mn2+ permeability records
in A549 cells after treatment with 0.5 mM Irvalec. The
graph corresponds to the mean 6 SEM values of [Ca2+]cyt in all
cells (n = 11) for two different experiments.
(TIF)
Figure S4 Analysis of P-glycoprotein expression in
A549-Irv cells. (A) Detection of P-glycoprotein protein expres-
sion by immunofluorescence using a specific antibody against this
efflux pump (B) The functional activity of P-gp in A549 cells was
analysed using the calcein-AM method. Briefly, the fluorescent
calcein-AM compound is a Pgp substrate that accumulates inside
cells when they do not express the efflux pump (green
fluorescence). In P-gp expressing cells, calcein-AM is rapidly
effluxed and thus, cells did not show the green fluorescence. The
figure shows representative images of calcein-AM accumulation in
A549-Irv cells. The LoVo/Dox cells were used as a control of a P-
glycoprotein positive cell line.
(TIF)
Figure S5 Chemical structures of fluorescent Irvalec
derivatives. (A) Irvalec-Oregon Green (B) Irvalec-AlexaFluor
555.
(TIF)
Figure S6 Localization of Irvalec in the plasma mem-
brane of A549-Irv cells. For these experiments, A549-Irv cells
were grown on LabTek chambered slides and treated with 4.6 mM
of a mix of 0.1 mM Irv-OG488 and non-labeled Irvalec ; cells were
analyzed by two-photon time-resolved fluorescence microscopy (A)
Representative 2P-FLIM image of a A549-Irv cell that did not
stain with Irv-OG488 (B) Representative 2P-FLIM image of Irv-
OG488 bound to the plasma membrane of a resistant cell. This
cell represents a minority population (,5%) of resistant cells in
which there was some interaction of Irvalec with the cell
membrane.
(TIF)
Table S1 Cytotoxic activity of a panel of anticancer
drugs in A549 cells resistant to Irvalec (A549-Irv). A549
and A549-Irv cell lines were treated with increasing concentrations
of all compounds and the cytotoxic effect was determined by the
MTT method after 72 h. Table shows mean IC50 values expressed
in mM and the Relative Resistance Index (IR) of A549-Irv with
regard to A549.
(DOC)
Video S1 Induction of necrosis by Irvalec. HeLa cells were
treated with 10 mM Irvalec and examined by real time phase
contrast video-microscopy.
(AVI)
Video S2 Irvalec induces the formation of giant vesicles
and necrosis. A549 cells were stained with AlexaFluor 488-
conjugated b-subunit of the cholera toxin to fluorescently label the
plasma membrane and subsequently treated with 10 mM Irvalec.
(AVI)
Video S3 Irvalec induces a rapid plasma membrane
permeabilization. Representative images of A549 cells exposed
to 10 mM Irvalec for 2 min. In the presence of propidium iodide,
unpermeabilized cells show intact nuclei while permeabilized cells
show PI stained nuclei.
(AVI)
Video S4 Irvalec induces a rapid plasma membrane
permeabilization. A549 cells were pre-loaded with calcein AM
and then treated with 10 mM Irvalec. The intracellular fluores-
cence rapidly vanished from permeabilized cells upon Irvalec
treatment.
(AVI)
Video S5 Protective effects of Zinc against Irvalec
cytotoxicity in tumor cells. A549 cells were treated with
5 mM Irvalec alone or in combination with 10 mM ZnCl2, in the
presence of propidium iodide. Cell permeabilization was followed
by fluorescence microscopy upon PI nuclear staining.
(AVI)
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